NSRX SCHEDULE 13G/A: SEC filing
Balyasny Asset Management L.P. and affiliated reporting persons
Filed with the SEC on · accession 0001172661-26-005053
NSRX filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Balyasny Asset Management L.P. and affiliated reporting persons filed an amended Schedule 13G disclosing beneficial ownership of approximately 9.99% of Nasus Pharma Ltd's common stock, consisting of 898,473 shares and 271,736 shares issuable upon exercise of warrants. The stock moved -7.3% by the first close after the filing.
Summary of the filing
Balyasny Asset Management L.P. and affiliated reporting persons filed an amended Schedule 13G disclosing beneficial ownership of approximately 9.99% of Nasus Pharma Ltd's common stock, consisting of 898,473 shares and 271,736 shares issuable upon exercise of warrants. The filing is a passive investment disclosure under Rule 13d-1(b).
Key details
How NSRX stock reacted
Close before
$2.87
Nov 13, 2026
First close after
-7.32%
$2.66
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for NSRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for NSRX?
Click hereFrequently asked questions
What did NSRX file with the SEC on Nov 16, 2026?
NSRX filed a SCHEDULE 13G/A (SEC filing). Balyasny Asset Management L.P. and affiliated reporting persons filed an amended Schedule 13G disclosing beneficial ownership of approximately 9.99% of Nasus Pharma Ltd's common stock, consisting of 898,473 shares and 271,736 shares issuable upon exercise of warrants. The filing is a passive investment disclosure under Rule 13d-1(b).
How do I read a SCHEDULE 13G/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).
How did NSRX stock react to this filing?
NSRX closed at $2.87 before the filing and $2.66 on Nov 16, 2026 (-7.32%).
Other NSRX SEC filings
- 6-K · Cfo changeNov 16, 2026
- 6-K · SEC filingOct 8, 2026
- 6-K · Secondary offeringSep 18, 2026
- 6-K · Fda approvalSep 14, 2026
- EFFECT · SEC filingSep 11, 2026
- 6-K · SEC filingSep 4, 2026
- EFFECT · SEC filingAug 20, 2026
- 6-K · Cfo changeAug 19, 2026
- 6-K · SEC filingAug 17, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
Get alerts when NSRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days